Statements (53)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:Company
|
gptkbp:activeDuring |
gptkb:parathyroid_hormone
|
gptkbp:administrativeDivision |
daily
|
gptkbp:availability |
prescription only
|
gptkbp:clinicalTrials |
Phase 3
ongoing studies positive outcomes multiple sites demonstrated in studies long-term management treatment of low calcium levels recommended for specific patient populations |
gptkbp:community_service |
available through manufacturer
|
gptkbp:communityPartnerships |
collaborations with universities
|
gptkbp:contraindication |
rare occurrences
hypersensitivity to the active ingredient |
gptkbp:date |
FDA_approved
|
gptkbp:developedBy |
gptkb:OPKO_Health,_Inc.
|
gptkbp:dosageForm |
injection
|
gptkbp:drugInterdiction |
none significant
subcutaneous absorption increases calcium levels in blood |
gptkbp:educational_programs |
provided to healthcare professionals
|
gptkbp:formulation |
liquid
sterile solution |
gptkbp:hasPopulation |
adults
|
gptkbp:healthcare |
important for adherence
|
https://www.w3.org/2000/01/rdf-schema#label |
OPKO 1400
|
gptkbp:insuranceAccepted |
may be covered
|
gptkbp:is_monitored_by |
calcium levels
|
gptkbp:lastProduced |
2016
|
gptkbp:mandates |
chronic hypoparathyroidism
|
gptkbp:manufacturer |
gptkb:Miami,_Florida
gptkb:OPKO_Health,_Inc. |
gptkbp:market |
available in pharmacies
|
gptkbp:marketedAs |
brand name
|
gptkbp:offers |
varies by location
|
gptkbp:packaging |
vial
|
gptkbp:patentStatus |
patented
|
gptkbp:produces |
gptkb:United_States
|
gptkbp:regulatoryCompliance |
granted_by_FDA
|
gptkbp:research_areas |
hormone replacement therapy
|
gptkbp:researchAndDevelopment |
ongoing
|
gptkbp:researchFocus |
endocrine disorders
|
gptkbp:route |
intravenous
|
gptkbp:safetyFeatures |
generally well tolerated
|
gptkbp:sideEffect |
headache
nausea injection site reactions |
gptkbp:storage |
refrigerated
|
gptkbp:supplyChain |
managed_by_OPKO_Health,_Inc.
|
gptkbp:targets |
hypoparathyroidism
|
gptkbp:usedFor |
diagnosing diseases
|